BIOCYTOGEN
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
Biocytogen’s RenLite® mice platform can produce fully human antibodies with diverse epitopes and high affinity. This platform is notable for its ability to generate antibodies in a common light chain format, offering a distinctive combination of design flexibility, simplified manufacturing processes, and optimal developability for bsADC development. Based on this platform, both companies will be able to discuss expanding their collaboration for various types of ADC development.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased to collaborate with ABL, a company that possesses advanced platforms for cancer immunotherapy and treatments against CNS diseases. ABL’s consistent success in advancing its pipeline strongly showcases its expertise and capabilities in regulatory, clinical development, and business development activities. BsADC drugs derived from our RenLite® mice platform have shown preferable potency in various tumor models, while also exhibiting good safety profiles. We believe our fully human bsADC platform technology, which features increased tumor selectivity, target synergized internalization, and convenient CMC development, will complement ABL's capabilities effectively. Together, we aim to expedite the development of innovative bsADC therapies.”
Sang Hoon Lee, CEO of ABL, said, “We are excited to establish this partnership with Biocytogen for bsADCs. This collaboration is one of the stepping stones for getting down to developing bsADCs. We look forward to a productive collaboration, and firmly believe that this partnership will contribute towards creating a distinctive pipeline, ultimately leading to novel therapies that improve the quality of life for patients.”
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
About ABL Bio
ABL Bio Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325027750/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlightSafety International Appoints Eric Hinson as Chief Executive Officer1.12.2025 23:00:00 CET | Press release
FlightSafety International Inc. today announced the appointment of Eric Hinson as chief executive officer, effective immediately. Hinson will succeed former president Barbara Telek who recently announced her retirement. Hinson’s appointment marks a return to FlightSafety. He served as an executive vice president from 2009 to 2012 before leaving to be the president and CEO of Simcom International, Inc. Hinson started his aviation career as a naval aviator flying tactical aircraft in training, fleet, and operational test squadrons. Today, he is an active ATP-rated pilot with more than 5,000 total flight hours. He brings a unique operational perspective to the position—one that blends executive leadership with firsthand experience. In addition to FlightSafety and Simcom, Hinson has served in a variety of senior leadership positions at leading aviation companies, including Honeywell, Gulfstream, and Piaggio Aerospace. He also served as a board member of the General Aviation Manufacturer As
Ubigi Voted Most Reliable eSIM for Mobile Professionals According to Latency Report 20251.12.2025 16:13:00 CET | Press release
Ubigi, a pioneer in eSIM solutions for travellers and connected professionals, has been ranked number one worldwide for connection quality according to the Latency Report 2025. This independent study evaluates eSIMs based on three key criteria: latency, jitter and packet loss. Thanks to its cutting-edge international network infrastructure, Ubigi has established itself as the benchmark for reliability for mobile professionals. Its architecture is based on seven Packet Gateways (P-GWs) spread across Europe, Asia and the Americas, allowing data to transit through the Internet point closest to the user. The result: latency reduced by a factor of two to five depending on the area and optimal stability for video conferencing, VPN and cloud services. Ubigi's performance, validated by the Latency Report 2025, stands out: Average latency: 35 ms in Europe, 92 ms in Asia; Jitter: only 5 ms; Packet loss: < 0.2%, one of the best reliability ratings measured. These results, confirmed by tests in Li
Rimini Street Announces Additional Stock Repurchase Transactions1.12.2025 15:00:00 CET | Press release
Company will share its vision, strategy, sales and execution model, financial model and guidance at its Investor Day event on December 3, 2025 Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the following: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201195169/en/ Rimini Street Announces Additional Stock Repurchase Transactions Share Repurchases The Company repurchased a total of 975,000 shares of common stock to date in the fourth fiscal quarter of 2025, for approximately $3.8 million with an average per share purchase price of $3.92, reducing outstanding shares by approximately 1.1%1. The Company has now completed and announced $13.3 million in common stock repurchases under its $50 million Common Stock Repurchase Plan that was app
MVNO Europe - Europe's Competitiveness Depends on a Truly Open Telecoms Market, Not on Increased Concentration That Benefits a Handful of Mobile Operators1.12.2025 14:37:00 CET | Press release
This is the warning that MVNO Europe – through its President Jacques Bonifay – has issued to the European Commission in an open letter to Ursula von der Leyen and Vice-President Henna Virkkunen. As discussions on the Digital Networks Act (DNA) enter their decisive phase, the association, which brings together alternative mobile operators in Europe, points out that the EU's digital ambition can only be achieved if competition remains a structuring principle, not an adjustment variable. While some players are calling for "necessary" consolidation in the sector, MVNO Europe warns against a simplistic and economically dangerous vision. "Reducing the number of operators has never guaranteed innovation, access for European industries, or fair conditions for new digital services. On the contrary, the historical driver of European competitiveness has always been the diversity of players, models, technologies and services," says Jacques Bonifay, President of MVNO Europe and CEO of Transatel. Re
IonQ and CCRM Announce Strategic Quantum-Biotech Collaboration to Accelerate Development of Advanced Therapeutics1.12.2025 13:30:00 CET | Press release
IonQ serves as strategic quantum technology partner across CCRM’s leading global regenerative medicine network IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an investment partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate next-generation therapeutic development using hybrid quantum and quantum-AI technologies. The partnership includes an investment commitment into CCRM’s new quantum-biotech initiatives and establishes IonQ as the core technology partner across CCRM’s global network of advanced therapy hubs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201706303/en/ IonQ serves as strategic quantum technology partner across CCRM’s leading global regenerative medicine network. With more than 100,000 square feet of good manufacturing practice (GMP) facilities, 300+ scientific staff and a global network of academic and industry partners, CCRM is one of t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom